Table1 Demographic and clinical profiles of PD patients and control groups.

From: Downregulation of blood serum microRNA 29 family in patients with Parkinson’s disease

 

Controls

PD

Hoehn&Yahr stage I

Hoehn&Yahr stage II

Hoehn&Yahr stage III

p Valuea

No. of subjects

80

80

29

25

26

—

Age, y

63.3 ± 5.4

64.0 ± 5.8

64.2 ± 5.9

63.0 ± 6.7

64.7 ± 5.0

0.777

F/M

32/48

32/48

12/17

12/13

8/18

0.807

Disease duration, mo

—

52.9 ± 52.2

23.7 ± 20.0

60.8 ± 63.7

77.8 ± 50.7d

0.001

UPDRS (motor)b

—

27.9 ± 14.0

16.6 ± 6.0

30.8 ± 9.2d

37.5 ± 15.6e

 < 0.001

Levodopa equivalent dose (mg/day)

—

312.4 ± 319.2

196.7 ± 269.4

301.7 ± 300.9

451.8 ± 343.4c

0.030

No. of drug-naïve patients

—

19

10

8

1

—

MMSE

—

27.4 ± 2.5

28.2 ± 1.4

26.9 ± 2.3

27.0 ± 3.4

0.331

  1. Abbreviations: PD = Parkinson disease; UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE = Mini Mental State Examination. The data are presented as mean ± SD.
  2. aAnalysis of variance with the exception of chi-square for gender.
  3. bOff-state motor ratings according to the UPDRS.
  4. cp < 0.05 vs. Hoehn & Yahr stage I group.
  5. dp < 0.01 vs. Hoehn & Yahr stage I group.
  6. ep < 0.001 vs. Hoehn & Yahr stage I group.
Back to article page